Compare Stocks → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLSNNASDAQ:EYEGNASDAQ:FCSCNASDAQ:SEELOTCMKTS:SEOVF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsEYEGAB Corporate Bond ETF$35.73+0.4%$1.90$1.44▼$8.18$450.85M0.81935,975 shs1 shsFCSCFibrocell Science$3.00$3.00$1.45▼$3.28$29.28M1.6778,673 shsN/ASEELSeelos Therapeutics$0.58-10.0%$0.94$0.37▼$49.80$7.87M1.97434,343 shs177,495 shsSEOVFSernova$0.41$0.44$0.37▼$0.83$124.52M1.1823,150 shs17,900 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%EYEGAB Corporate Bond ETF+0.43%+0.71%+1.31%-0.98%+1,732.20%FCSCFibrocell Science0.00%0.00%0.00%0.00%0.00%SEELSeelos Therapeutics+21.19%+16.66%-34.09%-55.91%-96.96%SEOVFSernova-0.17%-2.84%-11.95%-21.08%-34.73%[BUY ALERT] Our #1 A.I. Stock for March (Ad)It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/AN/AN/AN/ASEELSeelos Therapeutics1.7746 of 5 stars3.22.00.00.02.40.00.0SEOVFSernovaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunonN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/ASEELSeelos Therapeutics2.33Hold$70.0012,071.80% UpsideSEOVFSernovaN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00EYEGAB Corporate Bond ETF$10K45,085.04N/AN/A$1.26 per share28.36FCSCFibrocell Science$350K83.66N/AN/A$0.98 per share3.06SEELSeelos Therapeutics$2.20M3.58N/AN/A($3.42) per share-0.17SEOVFSernovaN/AN/AN/AN/A$0.12 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AEYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/AFCSCFibrocell Science-$10.28M-$1.45N/AN/AN/AN/A23.10%10.56%N/ASEELSeelos Therapeutics-$37.88MN/A0.00∞N/A-1,719.56%N/A-517.23%5/20/2024 (Estimated)SEOVFSernova-$28.91M-$0.09N/A∞N/AN/A-146.71%-114.00%6/12/2024 (Estimated)Latest FCSC, SEOVF, CLSN, EYEG, and SEEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q1 2024SEOVFSernovaN/A-$0.02-$0.02-$0.02N/AN/A1/29/2024Q4 2023SEOVFSernovaN/A-$0.03-$0.03-$0.03N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/ASEOVFSernovaN/AN/AN/AN/AN/ALatest FCSC, SEOVF, CLSN, EYEG, and SEEL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/20241/31/2024EYEGAB Corporate Bond ETFMonthly$0.14762/1/20242/2/20242/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52EYEGAB Corporate Bond ETF0.013.073.07FCSCFibrocell Science0.475.095.09SEELSeelos TherapeuticsN/A0.140.14SEOVFSernovaN/A3.233.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%EYEGAB Corporate Bond ETF64.16%FCSCFibrocell Science36.72%SEELSeelos Therapeutics23.37%SEOVFSernovaN/AInsider OwnershipCompanyInsider OwnershipCLSNImunon4.66%EYEGAB Corporate Bond ETF58.20%FCSCFibrocell Science1.10%SEELSeelos Therapeutics5.40%SEOVFSernovaN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableEYEGAB Corporate Bond ETF1412.62 million5.28 millionNot OptionableFCSCFibrocell Science199.76 millionN/AOptionableSEELSeelos Therapeutics1513.68 million12.94 millionOptionableSEOVFSernovaN/A303.41 millionN/ANot OptionableFCSC, SEOVF, CLSN, EYEG, and SEEL HeadlinesSourceHeadlineSernova Names Nicholas Rossettos Interim CFOmarketwatch.com - March 11 at 1:39 PMSernova reports anticipated 2024 milestonesmsn.com - January 29 at 10:40 AMSernova gets FDA orphan drug, rare pediatric designations for hemophilia Amsn.com - November 27 at 8:15 PMClosing Bell: Sernova Corp flat on Tuesday (SVA)theglobeandmail.com - November 14 at 9:04 PMSernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congressfinance.yahoo.com - October 30 at 7:35 AMSernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meetingfinance.yahoo.com - September 29 at 1:00 PMSernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Devicefinance.yahoo.com - September 7 at 10:11 AMSernova Appoints Cynthia Pussinen as Chief Executivemarketwatch.com - September 5 at 4:32 PMSernova appoints CEOseekingalpha.com - September 5 at 4:32 PMSernova reports positive interim data for Cell Pouch Systemmassdevice.com - June 26 at 6:49 PMSernova (SVA) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - June 26 at 8:00 AMSernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessionsfinance.yahoo.com - June 22 at 6:01 PMSernova is significantly undervalued, says Echeloncantechletter.com - June 16 at 11:36 PMSernova to Participate in Upcoming Truist Securities Cell Therapy Symposiumfinance.yahoo.com - June 16 at 1:35 PMEchelon Wealth Partners Remains a Buy on Sernova (SVA)markets.businessinsider.com - June 15 at 3:50 PMSernova Announces Executive Alignment and Appoints New Board Chairfinance.yahoo.com - May 31 at 8:58 AMClosing Bell: Sernova Corp flat on Monday (SVA)theglobeandmail.com - May 8 at 9:43 PMSernova Corp. Announces Voting Results of the 2023 Annual General Meeting of Shareholdersthenewswire.com - April 28 at 3:38 PMClosing Bell: Sernova Corp flat on Thursday (SVA)theglobeandmail.com - April 28 at 10:37 AMConcerned Shareholders of Sernova Corp. Wish to Thank All Shareholdersfinance.yahoo.com - April 25 at 6:02 PMSernova Reminds Shareholders to Vote FOR the Eight Management Director Nominees Using ONLY the WHITE Management Proxythenewswire.com - April 21 at 12:40 PMProxy adviser backs diabetes device developer Sernova in fight against activist investorsmedtechdive.com - April 17 at 3:33 PMSernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Medfinance.yahoo.com - April 10 at 8:20 AMSernova defends record after investors attack ‘sluggish’ progress of regenerative medicine implantmedtechdive.com - April 7 at 3:12 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.AB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.Fibrocell ScienceNASDAQ:FCSCFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Seelos TherapeuticsNASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.SernovaOTCMKTS:SEOVFSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.